CN104189400B - 一种治疗癌症的中药组合物及其制备方法 - Google Patents
一种治疗癌症的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN104189400B CN104189400B CN201410483839.5A CN201410483839A CN104189400B CN 104189400 B CN104189400 B CN 104189400B CN 201410483839 A CN201410483839 A CN 201410483839A CN 104189400 B CN104189400 B CN 104189400B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- weight portion
- semen
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 206010028980 Neoplasm Diseases 0.000 title abstract description 37
- 201000011510 cancer Diseases 0.000 title abstract description 26
- 230000001225 therapeutic effect Effects 0.000 title abstract description 9
- 210000000582 semen Anatomy 0.000 claims abstract description 37
- 241001489978 Eupolyphaga Species 0.000 claims abstract description 12
- 241000131808 Scolopendra Species 0.000 claims abstract description 12
- 239000002775 capsule Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 11
- 239000012567 medical material Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims 1
- 230000004083 survival effect Effects 0.000 abstract description 5
- 206010061428 decreased appetite Diseases 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 230000001934 delay Effects 0.000 abstract description 2
- 238000009792 diffusion process Methods 0.000 abstract description 2
- 239000003390 Chinese drug Substances 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 16
- 231100000614 poison Toxicity 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 8
- 239000003440 toxic substance Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 206010007247 Carbuncle Diseases 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010017553 Furuncle Diseases 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 230000036461 convulsion Effects 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000007096 poisonous effect Effects 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000003026 hypopharynx Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 230000002048 spasmolytic effect Effects 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241001250596 Pleione Species 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000222640 Polyporus Species 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000522620 Scorpio Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 244000107975 Strychnos nux-vomica Species 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- -1 absorption carrier Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 239000009490 scorpio Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410483839.5A CN104189400B (zh) | 2014-09-19 | 2014-09-19 | 一种治疗癌症的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410483839.5A CN104189400B (zh) | 2014-09-19 | 2014-09-19 | 一种治疗癌症的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104189400A CN104189400A (zh) | 2014-12-10 |
CN104189400B true CN104189400B (zh) | 2015-08-19 |
Family
ID=52074872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410483839.5A Expired - Fee Related CN104189400B (zh) | 2014-09-19 | 2014-09-19 | 一种治疗癌症的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104189400B (zh) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102028871B (zh) * | 2009-09-28 | 2012-05-09 | 魏保全 | 一种治疗胃癌和肝癌的膏药 |
-
2014
- 2014-09-19 CN CN201410483839.5A patent/CN104189400B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN104189400A (zh) | 2014-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105749179A (zh) | 治疗代谢综合征的中药组合物 | |
CN103285119A (zh) | 一种治疗自身免疫性肝病的中药组合物及其制备方法 | |
CN104147536A (zh) | 一种治疗痔疮的药物组合物及其制备方法 | |
CN103656461A (zh) | 一种治疗胃癌的中药蜜丸及制备方法 | |
CN103933450A (zh) | 一种预防或/和治疗胃肠疾病的中药组合物及其制备方法 | |
CN104138460A (zh) | 一种治疗颈腰腿痛的中药组合物及其制备方法 | |
CN105709074A (zh) | 一种治疗风湿性关节炎及骨质增生的药物及制备方法 | |
CN104225490A (zh) | 一种治疗胆囊炎的中药 | |
CN100431592C (zh) | 一种治疗***增生的中药制剂 | |
CN105770691A (zh) | 一种用于治疗***的药物制剂及其用途 | |
CN103520652B (zh) | 一种治疗肝癌的中药组合物 | |
CN104189400B (zh) | 一种治疗癌症的中药组合物及其制备方法 | |
CN101028421B (zh) | 一种治疗慢性肾衰的中成药 | |
CN103908616A (zh) | 缓解肿瘤病人放疗反应的药剂及制备方法 | |
CN103127398B (zh) | 一种治疗癌症的中药及其制备方法 | |
CN101829188A (zh) | 一种治疗***和结石病的药物 | |
CN101693096A (zh) | 一种治疗肝癌的药物及其制备方法 | |
CN109419844B (zh) | 一种治疗骨关节炎疼痛的藏药组合物 | |
CN104740013A (zh) | 一种治疗恶性肿瘤的中药组合物 | |
CN105079772A (zh) | 一种治疗术后早期粘连性肠梗阻的中药组合物 | |
CN105079771A (zh) | 一种治疗术后肠粘连性肠梗阻的中药组合物 | |
CN104623359A (zh) | 一种治疗小儿肺炎的中药 | |
CN105597020A (zh) | 一种治疗***合并乳腺增生的药物组合物 | |
CN106668704A (zh) | 回族中药参木胃癌散颗粒及其制备方法 | |
CN105597004A (zh) | 一种治疗癌症的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SUI ANKUI Free format text: FORMER OWNER: TANG GUOPING Effective date: 20150703 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Sui Ankui Inventor after: Zhang Xifeng Inventor after: Zhu Qing Inventor before: Tang Guoping |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: TANG GUOPING TO: SUI ANKUI ZHANG XIFENG ZHU QING |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150703 Address after: 266000, 1281, Ao Ao Road, Jimo, Shandong, Qingdao Applicant after: Sui Ankui Address before: 276017 Shandong Province, Luozhuang District Fu Zhuang Office after the village of coke, No. 5 Applicant before: Tang Guoping |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150819 Termination date: 20160919 |